Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6696 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6696पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −30.9x | −2.0x | −0.6x | |
PEG अनुपात | 0.89 | −0.16 | 0.00 | |
क़ीमत/बुक | 11.2x | 1.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 61.4x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 215.6% | 44.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.6% | 6.6% | अनलॉक करें |